View the JUBLIA vehicle fluorescein data       For the treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes1   JUBLIA® See how the vehicle reaches the infected nail bed         In a study of 11 patients, fluorescein was used to track the spread of the JUBLIA vehicle solution2*   • Under ultraviolet light, fluorescein revealed the areas between the nail and nail bed where the solution was able to reach2   • Two drops of the vehicle solution were applied only to the nail's distal end. For proper application instructions, click here   Subject after one application of JUBLIA vehicle solution with fluorescein2                   For a limited time, your eligible patients pay $0† for JUBLIA— click here to access offer and learn more        Clinical study results   JUBLIA is an effective azole antifungal formulated to reach the site of infection1,3   • In Study 1, JUBLIA achieved 17.8% (117/656) complete cure vs 3.3% (7/214) with vehicle1   • In Study 2, JUBLIA achieved 15.2% (88/580) complete cure vs 5.5% (11/201) with vehicle1   • Complete cure defined as 0% involvement of the target nail in addition to mycological cure, defined as both negative fungal culture and negative KOH1   Study Design: In 2 identical, multicenter, randomized, parallel-group, double-blind, vehicle-controlled studies, patients with mild to moderate toenail distal lateral subungual onychomycosis (defined as 20%-50% clinical involvement of the target toenail, without dermatophytomas or matrix [lunula] involvement) were randomized to efinaconazole 10% solution or vehicle.4           INDICATION JUBLIA (efinaconazole) topical solution, 10% is indicated for the topical treatment of onychomycosis (tinea unguium) of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.   IMPORTANT SAFETY INFORMATION   • JUBLIA is for topical use only and is not for oral, ophthalmic, or intravaginal use.   • Patients should be instructed to contact their health care professional if a reaction suggesting sensitivity or severe irritation occurs.   • The most common adverse reactions (incidence >1%) were (vs vehicle): ingrown toenail (2.3% vs 0.7%), application-site dermatitis (2.2% vs 0.2%), application-site vesicles (1.6% vs 0%), and application-site pain (1.1% vs 0.2%).   • JUBLIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and should be used with caution in nursing women. The safety and effectiveness in pediatric patients have not been established.   Click here for Prescribing Information or visit www.JubliaRx.com.     * Note: Vehicle did not contain active ingredient efinaconazole; included dye for illustrative purposes.1     † Offer valid only for commercially insured patients whose insurance covers JUBLIA. Commercially insured patients whose insurance does not cover JUBLIA may pay more. Not valid for patients reimbursed in whole or in part by federal health care programs, including Medicare, Medicaid, CHAMPUS, the Department of Veterans Affairs, state maternal and child health block grant programs under 42 U.S.C. 701 et. seq., state social service block grant programs under 42 U.S.C. section 1397 et. seq., or any other similar federal or state health care program. Void when prohibited by law, taxed, or restricted. Void outside the United States. See savings card for full eligibility terms and conditions here.   Patients with questions should call 855-264-0299.   References: 1. JUBLIA [prescribing information]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2014. 2. Elewski BE, Pollak R, Radhakrishnan P, et al. Access of efinaconazole topical solution, 10%, to the infection site by spreading through the subungual space. J Drugs Dermatol. 2014;13(11):611-615. 3. Data on file. Valeant Pharmaceuticals North America LLC. 4. Elewski BE, Rich P, Pollak R, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis: two phase III multicenter, randomized, double-blind studies. J Am Acad Dermatol. 2013;68(4):600-608.   Except as otherwise indicated, all product names, slogans, and other marks are trademarks of the Valeant family of companies.             You have the right to opt out of receiving unsolicited advertisements by e-mail. You may contact us with your opt-out request, along with the e-mail to which your request relates, by telephone at 1-877-540-6501, or by submitting your request to valeantorder@corpcomm.com. Opt-out requests will be honored within 10 business days of receipt. Please be sure to indicate the e-mail address to which your request relates and reason for opt-out.   © 2014 Valeant Pharmaceuticals North America LLC              DM/JUB/14/0172